Single and Multiple Ascending Dose Study to Evaluate AMG 786 in Healthy Participants and Participants With Obesity
NCT05406115 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 65
Last updated 2025-10-27
Summary
The primary objective of this study is to assess the safety and tolerability of AMG 786 as single or multiple doses in healthy and obese participants.
Conditions
Interventions
- DRUG
-
AMG 786
Oral tablet
- OTHER
-
Placebo
Oral tablet
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
MD · Amgen
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- DOUBLE
- Model
- SEQUENTIAL
Eligibility
- Min Age
- 18 Years
- Max Age
- 65 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2022-07-26
- Primary Completion
- 2023-08-21
- Completion
- 2023-08-21
- FDA Drug
- Yes
Countries
- United States
Study Locations
More Related Trials
-
A Study of SGB-7342 in Subjects With Obesity or Overweight
NCT07324850 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1
-
Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of BGM1812 Injection Following Single and Multiple Subcutaneous Administration in Normal to Overweight or Obese But Otherwise Healthy Men and Women
NCT07224399 ·Status: RECRUITING ·Phase: PHASE1
-
A Study to Evaluate AMG 133 Administered Subcutaneously in Participants With Overweight or Obesity
NCT06976372 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Compare Two Different Forms of PF-07081532 in Adults Who Are Overweight or Obese
NCT05677867 ·Status: COMPLETED ·Phase: PHASE1
-
A Research Study Investigating NNC0247-0829 for Weight Management in People With Overweight or Obesity
NCT04010786 ·Status: COMPLETED ·Phase: PHASE1
-
Safety Study to Evaluate BMS-830216 in Healthy Subjects
NCT00878020 ·Status: COMPLETED ·Phase: PHASE1
-
Safety, Pharmacokinetics and Pharmacodynamics Study to Evaluate BMS-830216 in Obese Subjects
NCT00909766 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Phase 1 Study of NGM313 in Healthy Adult Participants
NCT02708576 ·Status: COMPLETED ·Phase: PHASE1
-
Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of BGM0504 Injection in Non-diabetic Overweight or Obese Adult Subjects
NCT06714955 ·Status: COMPLETED ·Phase: PHASE1
-
Phase 1, Single Ascending Dose Study to Evaluate the Safety, Tolerability, PK, PD, and Comparative Bioavailability of THRV-1268 in Obese Adult Participants
NCT07186946 ·Status: COMPLETED ·Phase: PHASE1
-
Study of Once-Daily Oral RGT001-075 Compared With Placebo in Adults With Obesity or Are Overweight With Weight-Related Health Conditions
NCT06867718 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Phase IIb One Year Efficacy and Safety Study of S-2367 in Obese Subjects With Reduced Calorie Diet
NCT00747929 ·Status: COMPLETED ·Phase: PHASE2
-
A Trial to Compare the Extent to Which Maridebart Cafraglutide (AMG 133) is Made Available in the Body When Administered Using Two Subcutaneous Presentations
NCT07313761 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Dose-ranging Study to Evaluate the Efficacy, Safety, and Tolerability of AMG 133 in Adult Subjects With Overweight or Obesity, With or Without Type 2 Diabetes Mellitus
NCT05669599 ·Status: COMPLETED ·Phase: PHASE2
-
Assessment of the Safety, Tolerability, and Pharmacokinetic of GMA106
NCT05054530 ·Status: COMPLETED ·Phase: PHASE1
-
An Investigational Drug Study in Obese (Considerably Overweight) Patients (0364-006)
NCT00109148 ·Status: COMPLETED ·Phase: PHASE2
-
Evaluate the Efficacy and Safety of NT-0796 in Participants With Obesity With or Without Type 2 Diabetes Mellitus
NCT07055516 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
A Study Evaluating the Effect of Daily Oral RO7795081 in Participants With Obesity or Overweight With at Least One Weight-Related Comorbidity
NCT07081958 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MBX 4291 in Adult Participants With Obesity
NCT07142707 ·Status: RECRUITING ·Phase: PHASE1
-
A Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MK-5823 in Overweight or Obese Participants Who Are Healthy or Have Type 2 Diabetes Mellitus (MK-5823-002)
NCT01614782 ·Status: TERMINATED ·Phase: PHASE1
-
A Single and Multiple Ascending Dose Study of HM17321 in Healthy and Obese Participants
NCT07219589 ·Status: RECRUITING ·Phase: PHASE1
-
Phase IIb One Year Efficacy and Safety Study of S-2367 in Obese Subjects With Initial 6-Week Low Calorie Diet
NCT00748605 ·Status: COMPLETED ·Phase: PHASE2
-
Safety, Pharmacokinetics and Potential Activity of HE3286 in Obese Adult Subjects
NCT00555451 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Evaluate the Efficacy and Safety of PF-06882961 in Adults With Obesity
NCT04707313 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Learn About the Study Medicine Called PF-07976016 in Adults With Obesity
NCT06717425 ·Status: COMPLETED ·Phase: PHASE2